219 related articles for article (PubMed ID: 17964711)
21. Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Sztriha LK; Sas K; Seres E; Boda K; Lenti L; Csifcsak G; Kovacs N; Vecsei L
Acta Neurol Scand; 2008 Apr; 117(4):250-4. PubMed ID: 17961197
[TBL] [Abstract][Full Text] [Related]
22. Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients.
Acikel S; Yildirir A; Aydinalp A; Demirtas K; Bal U; Kaynar G; Ozin B; Karakayali H; Muderrisoglu H; Haberal M
Transplant Proc; 2008 Dec; 40(10):3485-8. PubMed ID: 19100419
[TBL] [Abstract][Full Text] [Related]
23. Screening for aspirin resistance in stable coronary artery patients by three different tests.
Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I
Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of aspirin resistance measured by PFA-100.
Coma-Canella I; Velasco A; Castano S
Int J Cardiol; 2005 May; 101(1):71-6. PubMed ID: 15860386
[TBL] [Abstract][Full Text] [Related]
25. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Alvarez-Sabín J; Penalba A; Quintana M; Krupinski J; García-Bonilla L; Montaner J
Cerebrovasc Dis; 2009; 28(4):371-7. PubMed ID: 19641312
[TBL] [Abstract][Full Text] [Related]
26. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882
[TBL] [Abstract][Full Text] [Related]
27. Aspirin non-responder status and early neurological deterioration: a prospective study.
Bugnicourt JM; Roussel B; Garcia PY; Canaple S; Lamy C; Godefroy O
Clin Neurol Neurosurg; 2011 Apr; 113(3):196-201. PubMed ID: 21145162
[TBL] [Abstract][Full Text] [Related]
28. The effectiveness of antiplatelet treatment with aspirin in polymorbid patients.
Paluch Z; Jedlicková V; Skibova J; Adamek T; Alusík S
Int Angiol; 2007 Sep; 26(3):206-12. PubMed ID: 17622200
[TBL] [Abstract][Full Text] [Related]
29. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
30. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
[TBL] [Abstract][Full Text] [Related]
31. Sex difference in the antiplatelet effect of aspirin in patients with stroke.
Cavallari LH; Helgason CM; Brace LD; Viana MA; Nutescu EA
Ann Pharmacother; 2006 May; 40(5):812-7. PubMed ID: 16608908
[TBL] [Abstract][Full Text] [Related]
32. Aspirin non-responder in Thai ischemic stroke patients.
Suanprasert N; Yadee T; Mahasirimongkol S; Jongjaroenprasert W; Tantirithisak T
J Med Assoc Thai; 2013 May; 96(5):523-30. PubMed ID: 23745305
[TBL] [Abstract][Full Text] [Related]
33. [Incidence of aspirin resistance in the patient group of a university hospital in Korea].
Lee YK; Kim HS; Park JY; Kang HJ
Korean J Lab Med; 2008 Aug; 28(4):251-7. PubMed ID: 18728372
[TBL] [Abstract][Full Text] [Related]
34. [Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
Stejskal D; Prosková J; Lacnák B; Horalík D; Hamplová A; Oral I; Hrabovská I; Ochmanová R; Adamovská S; Juráková R; Ozanová G; Juchelka J; Kulísková O; Pĕnkavová H
Vnitr Lek; 2004 Aug; 50(8):591-9. PubMed ID: 15521202
[TBL] [Abstract][Full Text] [Related]
35. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease.
Kunicki TJ; Williams SA; Nugent DJ; Harrison P; Segal HC; Syed A; Rothwell PM
Thromb Haemost; 2009 Jan; 101(1):123-33. PubMed ID: 19132198
[TBL] [Abstract][Full Text] [Related]
36. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
37. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici M; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(6):608-13. PubMed ID: 19407444
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke.
Agayeva N; Gungor L; Topcuoglu MA; Arsava EM
J Stroke Cerebrovasc Dis; 2015 Apr; 24(4):745-50. PubMed ID: 25680657
[TBL] [Abstract][Full Text] [Related]
39. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry.
Nielsen HL; Kristensen SD; Thygesen SS; Mortensen J; Pedersen SB; Grove EL; Hvas AM
Thromb Res; 2008; 123(2):267-73. PubMed ID: 18499236
[TBL] [Abstract][Full Text] [Related]
40. Aspirin resistance and adverse clinical events in patients with coronary artery disease.
Chen WH; Cheng X; Lee PY; Ng W; Kwok JY; Tse HF; Lau CP
Am J Med; 2007 Jul; 120(7):631-5. PubMed ID: 17602938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
